Bio-Techne Corp
NASDAQ:TECH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Sinyi Realty Inc
TWSE:9940
|
TW |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its 3-Year Average (37.9), the stock would be worth $66.07 (11% upside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 34.1 | $59.53 |
0%
|
| 3-Year Average | 37.9 | $66.07 |
+11%
|
| 5-Year Average | 44 | $76.84 |
+29%
|
| Industry Average | 29.2 | $50.94 |
-14%
|
| Country Average | 19.6 | $34.25 |
-42%
|
Forward EV/EBIT
Today’s price vs future ebit
| Today's Enterprise Value | EBIT | Forward EV/EBIT | ||
|---|---|---|---|---|
|
$9B
|
/ |
Jan 2026
$274.6m
|
= |
|
|
$9B
|
/ |
Jun 2026
$405.1m
|
= |
|
|
$9B
|
/ |
Jun 2027
$443.1m
|
= |
|
|
$9B
|
/ |
Jun 2028
$501.7m
|
= |
|
Forward EV/EBIT shows whether today’s EV/EBIT still looks high or low once future ebit are taken into account.
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Bio-Techne Corp
NASDAQ:TECH
|
8.9B USD | 34.1 | 116.1 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1T USD | 2 292.9 | 4 155.7 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
194.1B USD | 27.4 | 29.7 | |
| US |
|
Danaher Corp
NYSE:DHR
|
137B USD | 28.3 | 38.3 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 39.4 | 46.1 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
36.5B CHF | 28.2 | -132.7 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
315.3B CNY | 17.3 | 16.5 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
33.4B USD | 23 | 26.6 | |
| US |
|
Waters Corp
NYSE:WAT
|
31.3B USD | 40.6 | 50 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
29.2B USD | 18.4 | 22.3 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
26.3B USD | 25.7 | 31.3 |
Market Distribution
| Min | 0 |
| 30th Percentile | 13.6 |
| Median | 19.6 |
| 70th Percentile | 27.8 |
| Max | 1 826 183.2 |
Other Multiples
Bio-Techne Corp
Glance View
Bio-Techne Corp. began its journey with a clear focus: to bridge the gap between biological research and practical applications, a mission that it continues to pursue with zeal. At its core, Bio-Techne operates as a pioneer in the production and distribution of biotechnology products, catering to the needs of the scientific community across the globe. The company specializes in providing essential tools for life sciences research, including proteins, antibodies, and reagents, empowering researchers to explore and innovate in fields ranging from cancer biology to neuroscience. These offerings are developed with meticulous care and a deep understanding of the scientific process, which positions Bio-Techne as a trusted ally to laboratories and research institutions worldwide. The financial heartbeat of Bio-Techne lies in its diverse portfolio, which extends into clinical diagnostics and genomics, segments that are critical in an era of personalized medicine and rapid technological advancement in healthcare. The company's revenue streams are robust, driven by a strategic blend of direct sales and collaborations with major pharmaceutical and biotech companies. Furthermore, Bio-Techne smartly leverages its acquisitions to fortify its market position, enhancing its capabilities and expanding its product lines. This agility and foresight not only enable Bio-Techne to sustain its growth trajectory but also to continually meet the ever-evolving demands of a fast-paced, innovation-driven industry.
